Imugene Ltd has released a press release.
Clarification Announcement
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Imugene
- Termination of Supply Agreement
- Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
- Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
- Imugene HER-Vaxx Clinical Trial Collaboration with Merck
- Oncolytic Virotherapy CF33 Patent Granted in Japan
Later from Imugene
- IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
- Imugene doses first patient in vaxinia phase 1 trial
- Final HER-Vaxx Phase 2 Trial Overall Survival Results
- Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
- First cohort 3 patient dosed in clinical trial of checkvacc
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene